Whereas it remains uncertain if excess plasma CXCL14 in IPF patients stems from lung tissue, data from tumor patients before and after treatment indicated that increased plasma CXCL14 levels originated from the lung62. This evidence concerns the gene CXCL14 and neoplasm.